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We present a case of feminizing adrenal carcinoma with severe elevation in serum estradiol and otherwise unexplained congestive
heart failure with ventricular arrhythmia and review the literature on feminizing adrenal tumors and the potential relationship
between estrogen and cardiac problems. A 54-year-old man presented with congestive heart failure and ventricular arrhythmia.
Imaging revealed a large adrenal mass. Hormonal evaluation revealed a very high serum level of estradiol, elevated DHEA-sulfate
and androstenedione, and lack of cortisol suppression on a low-dose overnight dexamethasone suppression test. The patient
underwent a left adrenalectomy with subsequent normalization of serum estradiol. Surgical pathology examination established
adrenocortical carcinoma MacFarlane stage II. Upon 15-month followup, the patient continued to have a normal serum estradiol
level, his cardiac function was significantly improved, and he had no further episodes of ventricular arrhythmia. To the best of our
knowledge, the serum estradiol level that was detected in our case is the highest that has been reported. Further, we hypothesize
that the very high serum concentration of estradiol in our case may have played a role in his cardiac presentation with congestive
heart failure and arrhythmia, particularly as these problems resolved with normalization of his serum estradiol level.
1. Introduction
Estradiol-secreting adrenal tumors are rare but are included
in the diﬀerential diagnosis of gynecomastia. We present
a case of a man with feminizing adrenocortical carcinoma
associated with extremely high levels of estradiol. We review
the literature on the potential eﬀects of estradiol on cardiac
function and cardiac arrhythmias.
2. Case Presentation
A 54-year-old African American male with a 2-year his-
tory of hypertension, heart failure, and diabetes mellitus
presented with progressive dyspnea and edema. He was
evaluated for decompensated heart failure and had episodes
of nonsustained ventricular tachycardia. An echocardiogram
revealed dilated left-sided chambers and moderate global
hypokinesis with ejection fraction of 35–40% (Table 1).
He was treated and stabilized and transferred to our insti-
tution for consideration of internal defibrillator placement.
Upon further questioning, the patient reported a 20 lb
weight loss, decreased libido, erectile dysfunction, and breast
development for the past 1-2 years.
Physical examination revealed stable vital signs (blood
pressure 122/66, pulse 100 and regular) and normal weight
(body mass index 23). At the time of our evaluation, he did
not have rales on lung examination, S3 gallop, or peripheral
edema. He had no Cushingoid features. Examination of
the chest demonstrated gynecomastia and a hyperdynamic
precordium. Examination of the abdomen revealed a firm
mass in the left upper quadrant. Genitourinary examination
was significant for soft 20mL testes with no masses.
Imaging studies showed an elevated left hemidiaphragm
on chest radiograph and a large abdominal mass (12 ×
11 × 17 cm) in the left upper quadrant on CT scan. This
mass displaced the left kidney and was felt to arise from
2 Case Reports in Endocrinology
Table 1: Echocardiography results.
Preoperation 17-month postoperation
Left atrium dimension (cm) (normal 3.0–4.0 cm) “moderately enlarged” 3.9
Left atrium vol/index (mL/m2) (normal 22 ± 6mL/m2) “moderately enlarged” 41
Left ventricle dimension (cm) (normal 4.2–5.9 cm) 7.1 5.1
Estimated ejection fraction (normal 50–80%) 35–40% 60–65%
Estimated pulmonary artery pressure (mmHg) (normal 9–18mmHg) 35–40 23.7
the left adrenal gland. Serum estradiol level was 3853 pg/mL,
(normal range < 52 in males); this level was confirmed on
repeat. Other pertinent hormonal evaluation included lack
of cortisol suppression after low-dose dexamethasone, mildly
elevated 24 hour urine free cortisol, elevated DHEA-S and
androstenedione, and suppressed plasma ACTH (Table 2).
12 lead electrocardiogram showed normal sinus rhythm
with a prolonged corrected QT interval of 477msec and
nonspecific anterior T wave abnormalities.
Chest CT, abdominal MRI (Figure 1), and bone scan
revealed no apparent metastases. Tumor resection and
removal of the left adrenal gland, left kidney, spleen, and
distal pancreas were performed. Pathology demonstrated
a 932 gm adrenocortical carcinoma measuring 17 cm ×
12 cm × 9 cm (Figure 2). Microscopic examination of the
adrenal tumor revealed diﬀuse growth pattern, vascular
invasion, necrosis, broad fibrous bands, and capsular inva-
sion. Immunohistochemical stains showed the tumor cells
to be positive for inhibin, MART-1, and negative for
chromogranin, EMA, and pankeratin AE1 : 3, with adequate
controls. Biopsy of ten regional lymph nodes was negative for
malignancy. The pathologic stage was pT2, pN0, and pMx.
The patient received stress dose steroids with a rapid taper
to physiologic replacement. He did well postoperatively, and
his estradiol level declined to <30 pg/mL. The patient was
discharged on carvedilol, furosemide, metformin, glipizide,
and NPH insulin with plans for further followup and
treatment at another medical center. However, he was unable
to aﬀord to follow through with this.
The patient returned to our endocrinology clinic 15
months following his surgery. He had noted improvement in
gynecomastia. He denied palpitations, dyspnea, orthopnea,
or chest pain and had not required any treatment for
heart failure or arrhythmia in the interim. He continued
on carvedilol, furosemide, glipizide, and NPH insulin. His
weight had remained stable. Physical examination was
remarkable for blood pressure 107/65, pulse 79 and regular,
mild gynecomastia, normal cardiovascular and respiratory
examination, and no peripheral edema. Serum estradiol level
remained normal (Table 2). Unfortunately other adrenal
hormone levels could not be retested due to financial con-
straints. On follow-up 12-lead electrocardiogram, corrected
QT interval was normal at 396msec. His diuretic was
discontinued. He did not redevelop any signs or symptoms of
heart failure. Echocardiogram done 2 months later revealed
significant improvement in cardiac function with an ejection
fraction of 60–65% and normal left ventricular dimensions,
but persistent left atrial dilatation (Table 1).
3. Discussion
Adrenocortical carcinomas (ACC) are rare, with 1-2 cases
per million patients [1]. Adrenal steroid hormone excess is
evident in 40–60% of cases [1]. Cushing’s syndrome is the
most frequent presentation [1]. The incidence of feminizing
ACC is much lower, being 1-2% of all ACC [2]. Feminizing
ACC in males leads to gynecomastia, diminished libido
and sexual potency, feminizing hair change, and testicular
atrophy [2]. Our patient’s serum estradiol level was extremely
high at 3853 pg/mL, with normal for a male <52 pg/mL. The
highest estradiol level previously reported in a male patient
with adrenal carcinoma is 1065 pg/mL [2].
In assessing adrenocortical carcinoma, consideration is
given to characteristics suggestive of poor prognosis. These
include older age at presentation, tumor size > 6 cm,
MacFarlane Stage III-IV, elevated level of estrogen, mixed
excretion of other steroids, nuclear atypia and capsular or
vascular invasion, and persistence or recurrence of elevated
hormone levels [2]. Our patient’s tumor was well over 6 cm,
was MacFarlane stage II, and had autonomous secretion
of cortisol and nuclear atypia and capsular and vascular
invasion (Figure 2). Serum estradiol level was extremely high
pre-op, but undetectable post-op.
Interestingly, our patient presented with congestive heart
failure (CHF). It has been noted in the literature that males
with CHF with low or high levels of estradiol demonstrate
increased mortality when compared to the mean [3]. A case
report from 1962 describes a case of CHF felt to be induced
by high-dose estrogen in the form of stilbestrol, used at that
time for treating duodenal ulcers. The signs and symptoms of
CHF resolved with no other therapy than rest andwithdrawal
of estrogen [4]. In a study from 1953 using very high doses
of stilbestrol to treat breast cancer, five patients who had
no evidence of CHF prior to treatment died of CHF after
treatment. The mechanism was felt to be estrogen-induced
salt and water retention [5].
Zhan et al. studied the dose eﬀect of estradiol replace-
ment on mortality and cardiac remodeling and dysfunction
post-myocardial infarction in ovariectomizedmice. Estradiol
tended to be cardioprotective at a low dose, but was
cardiotoxic at supraphysiologic levels. The highest dose of
estradiol increased plasma estrogen 8.5 fold [6]. This estra-
diol concentration does not approach the same magnitude
found in our patient.
Our patient was transferred to our hospital for cardiac
arrhythmia. Gender diﬀerences in cardiac electrophysiology
have been reported for over a century [7]. Eﬀects of sex
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Table 2: Hormonal evaluation.
Pre-operation
Immediately
postoperation
At 15-month
followup
Reference Range
ACTH (pg/mL) <5 7–50
AM cortisol (μg/dL) 27.7
Cortisol after overnight 1mg dexamethasone
suppression (μg/dL)
23.6 <1.8
Androstenedione (ng/dL) 375 50–220
DHEA-S (μg/dL) 726 39 25–240
Plasma metanephrine (pg/mL) <25 ≤57
Plasma normetanephrine (pg/mL) <25 ≤148
Total metanephrines (pg/mL) <50 ≤205
Aldosterone (ng/dL) <1 ≤28 (upright 8 am–10 am)
Plasma renin activity (ng/mL/hr) 2.8 0.65–5.0 (upright)
Estradiol (pg/mL) 3853 <30 25.2 <52 (males)
24 hr urine free cortisol (mcg/24 hrs) 56.7 Not measured Not measured 4.0–50.0
24 hr urine volume (mL) 2080
Figure 1: Magnetic resonance image of the abdomen demonstrating the left adrenal mass in transverse and coronal planes.
hormones on cardiac electrophysiology have been studied
in humans, animals, and cell models. In males, electro-
physiologic diﬀerences become apparent during adolescence
when the QT interval shortens. This has been correlated
to testosterone levels. Estrogen has the opposite eﬀect. QT
intervals have been found to slightly increase with estrogen
replacement therapy in postmenopausal women [8]. Inap-
propriate sinus tachycardia, AV nodal reentry tachycardia,
sick sinus syndrome, idiopathic right ventricular tachycardia,
and long QT arrhythmias are more common in women [7].
In a recent editorial review, Ciacco highlighted the
relationship between torsades de pointes, sex hormones, and
ventricular repolarization. He pointed out that women are
2-3 times more likely to experience episodes of torsades
compared to men, risk of torsades increases with prolonged
QT interval over 500ms, and females have longer baseline
QT intervals [9]. Elevated estrogen levels reduce potassium
channel currents in a dose-dependent manner, causing
action potential duration, and thus repolarization, to be
delayed, which increases susceptibility to arrhythmia [8, 10].
Women appear to be more susceptible to drug-induced tor-
sades [8]. A recent study done in model cells and tissues sug-
gested high estradiol concentrations increased susceptibility
to arrhythmias via QT prolongation [10]. Chen et al. found
a higher incidence of torsades in dogs receiving cisapride
(a drug known to increase QT interval) and estradiol than
in those receiving cisapride alone. The change in QT with
high dose estradiol alone was approximately 25msec—this
was with average plasma estradiol level 1615 pg/mL [11].
The change in our patient’s QT interval between his pre-
and post-op electrocardiogram suggests estrogen may have
been aﬀecting his cardiac repolarization. However, the eﬀects
of very high levels of estrogen on the heart are still poorly
understood.
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(a) Gross Appearance of Adrenal Mass (b) H&E ×100
(c) H&E ×200 (d) H&E ×40
Figure 2: (a) Adrenocortical carcinoma weight 932 grams, (b) lymphovascular invasion, (c) oncocytic cells with frequent mitotic figures,
and (d) capsular invasion.
The possible contribution of other adrenal hormones to
our patient’s cardiomyopathy cannot be ruled out. It is
possible that cortisol excess, as demonstrated by an abnor-
mal result on 1mg dexamethasone suppression testing, as
well as a suppressed plasma ACTH level, was a factor in
his cardiac presentation; however, urine free cortisol was
only moderately elevated at 56.7mcg/24 hrs (normal 4–
50.0). Cardiac involvement in Cushing’s syndrome occurs
primarily in the form of left ventricular hypertrophy and
diastolic dysfunction [12]. There have been a few case reports
of Cushing’s patients with dilated cardiomyopathy, which
was fully reversed after treatment [13]. The mechanism of
this dilated cardiomyopathy has not been defined. The fact
that our patient’s serum aldosterone was low at <1 ng/dL
(normal ≤ 28 upright) rules out aldosterone excess. The fact
that his plasma renin was not suppressed suggests that it was
unlikely that a diﬀerent mineralocorticoid such as deoxycor-
ticosterone was present in excess. Deoxycorticosterone was
not measured in our patient.
The patient also had elevated levels of DHEA-S 726mcg/
dL (normal 25–240) and androstenedione 375 ng/dL (nor-
mal 50–220). DHEA-S level normalized after surgery. Studies
have suggested that among men, low DHEA-S levels have
been consistently associated with an increased risk of all-
cause mortality and cardiovascular disease [14, 15]. We
found no studies correlating high levels of DHEA-S and
cardiac disease.
We acknowledge that diabetes and hypertension could
have contributed to this patient’s cardiomyopathy; however,
these causes alone would not explain the significant improve-
ment in his cardiac function after surgery for his adrenal
tumor.
4. Conclusion
An important take home message of this case is that a
middle-aged man with new onset gynecomastia should be
evaluated with a hormonal panel to search for pathologic
causes, including an estradiol level to screen for the rare case
of a feminizing tumor.
In addition, this case highlights the possibility that
the patient’s uniquely high serum level of estradiol due
to adrenal carcinoma may have contributed to arrhythmia
by prolonging his QT interval, which normalized with
normalization of serum estradiol level after surgery. It is also
possible that the high concentration of estrogen contributed
to his congestive heart failure due to dilated cardiomyopathy,
which also resolved with normalization of serum estradiol.
This unique clinical model appears to support previous
observations on the cardiac eﬀects of estrogen.
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